FDA staff raises efficacy concerns for Otsuka's PTSD combination drug-March 2024-www.financetom.com

FDA staff raises efficacy concerns for Otsuka's PTSD combination drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA staff raises efficacy concerns for Otsuka's PTSD combination drug

Jul 16, 2025 6:26 AM

July 16 (Reuters) - The U.S. Food and Drug

Administration's staff reviewers on Wednesday raised efficacy

concerns over Otsuka Pharma's combination treatment for

adults with post-traumatic stress disorder (PTSD), citing

inconsistent trial results and a modest treatment effect that

may not be clinically meaningful.

Previous page： Atour Lifestyle Q3 Adjusted Earnings, Revenue Rise; Shares Up Pre-Bell Next page： Xoriant Acquires TestDevLab to Expand European Presence & AI-Driven QE Capabilities

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Atour Lifestyle Q3 Adjusted Earnings, Revenue Rise; Shares Up Pre-Bell

Nov 25, 2025

06:26 AM EST, 11/25/2025 (MT Newswires) -- Atour Lifestyle ( ATAT ) reported Q3 adjusted earnings Tuesday of 1.16 Chinese renminbi ($0.16) per diluted share, up from 0.93 renminbi a year earlier. Net revenue for the quarter ended Sept. 30 was 2.63 billion renminbi, compared with 1.9 billion renminbi a year earlier. Analysts surveyed by FactSet expected 2.46 billion renminbi....

Xoriant Acquires TestDevLab to Expand European Presence & AI-Driven QE Capabilities

Nov 25, 2025

SUNNYVALE, Calif. & RIGA, Latvia--(BUSINESS WIRE)-- Xoriant, a ChrysCapital-owned global engineering and technology services company, announced the acquisition of TestDevLab, a Latvia‑headquartered leader in software quality engineering. This is Xoriant’s fourth acquisition in the last 3 years as the company rapidly scales globally with operations in 28 offices across India, the United States, and Europe. TestDevLab’s Baltic and Macedonian delivery...

OrganiGram Hires James Yamanaka as CEO

Nov 25, 2025

06:29 AM EST, 11/25/2025 (MT Newswires) -- Organigram Global ( OGI ) said Tuesday that it has appointed James Yamanaka as chief executive officer, effective on or about Jan. 15. Yamanaka was most recently the global head of strategy for British American Tobacco, Organigram said. Organigram also said chairman Peter Amirault will serve as executive chair on an interim basis...

Form 8.3

Nov 25, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...